132 related articles for article (PubMed ID: 26779635)
1. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI.
Kozakiewicz B; Chądzyńska M; Dmoch-Gajzlerska E; Stefaniak M
Tumour Biol; 2016 Jul; 37(7):9367-74. PubMed ID: 26779635
[TBL] [Abstract][Full Text] [Related]
2. Tumor-associated trypsin inhibitor in patients with endometrial cancer.
Kozakiewicz B; Chądzyńska M; Dmoch-Gajzlerska E; Stefaniak M
Tumori; 2016 Oct; 102(5):527-532. PubMed ID: 26350184
[TBL] [Abstract][Full Text] [Related]
3. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.
Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H
Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497
[TBL] [Abstract][Full Text] [Related]
4. CEA change after neoadjuvant chemotherapy including bevacizumab and clinical outcome in patients undergoing liver resection for colorectal liver metastases.
Stremitzer S; Stift J; Graf A; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
Ann Surg Oncol; 2015 Apr; 22(4):1315-23. PubMed ID: 25323471
[TBL] [Abstract][Full Text] [Related]
5. Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.
Gaber A; Nodin B; Hotakainen K; Nilsson E; Stenman UH; Bjartell A; Birgisson H; Jirström K
BMC Cancer; 2010 Sep; 10():498. PubMed ID: 20849596
[TBL] [Abstract][Full Text] [Related]
6. Combined modality therapy for rectal cancer: the relative value of posttreatment versus pretreatment CEA as a prognostic marker for disease recurrence.
Song S; Hong JC; McDonnell SE; Koong AC; Minsky BD; Chang DT; Liauw SL
Ann Surg Oncol; 2012 Aug; 19(8):2471-6. PubMed ID: 22327251
[TBL] [Abstract][Full Text] [Related]
7. TATI (tumor associated trypsin inhibitor) and cancer antigen 125 (CA 125) in patients with early-stage endometrial cancer.
Peters-Engl C; Buxbaum P; Ogris E; Sevelda P; Medl M
Anticancer Res; 1998; 18(6B):4635-9. PubMed ID: 9891532
[TBL] [Abstract][Full Text] [Related]
8. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
9. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma.
Leminen A
Gynecol Oncol; 1990 Dec; 39(3):358-63. PubMed ID: 2258083
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
11. Carcinoembryonic antigen (CEA)--a useful marker for the detection of recurrent disease in endometrial carcinoma patients.
Bruns F; Micke O; Halek G; Schäfer U; Willich N
Anticancer Res; 2003; 23(2A):1103-6. PubMed ID: 12820355
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors affecting recurrence and survival in patients with locally advanced rectal cancer.
Koca D; Binicier C; Oztop I; Yavuzsen T; Ellidokuz H; Yilmaz U
J BUON; 2012; 17(2):291-8. PubMed ID: 22740208
[TBL] [Abstract][Full Text] [Related]
13. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
14. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
[TBL] [Abstract][Full Text] [Related]
15. Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases.
Araujo RL; Gönen M; Allen P; DeMatteo R; Kingham P; Jarnagin W; D'Angelica M; Fong Y
Ann Surg Oncol; 2015 Sep; 22(9):3087-93. PubMed ID: 25582745
[TBL] [Abstract][Full Text] [Related]
16. Synuclein gamma predicts poor clinical outcome in colon cancer with normal levels of carcinoembryonic antigen.
Liu C; Dong B; Lu A; Qu L; Xing X; Meng L; Wu J; Eric Shi Y; Shou C
BMC Cancer; 2010 Jul; 10():359. PubMed ID: 20604972
[TBL] [Abstract][Full Text] [Related]
17. Serum carcinoembryonic antigen monitoring after curative resection for colorectal cancer: clinical significance of the preoperative level.
Park IJ; Choi GS; Lim KH; Kang BM; Jun SH
Ann Surg Oncol; 2009 Nov; 16(11):3087-93. PubMed ID: 19629600
[TBL] [Abstract][Full Text] [Related]
18. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated trypsin inhibitor, carcinoembryonic antigen and acute-phase reactant proteins CRP and alpha1-antitrypsin in patients with gastrointestinal malignancies.
Solakidi S; Dessypris A; Stathopoulos GP; Androulakis G; Sekeris CE
Clin Biochem; 2004 Jan; 37(1):56-60. PubMed ID: 14675563
[TBL] [Abstract][Full Text] [Related]
20. Improved tumour marker sensitivity in detecting colorectal liver metastases by combined type IV collagen and CEA measurement.
Nyström H; Tavelin B; Björklund M; Naredi P; Sund M
Tumour Biol; 2015 Dec; 36(12):9839-47. PubMed ID: 26162539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
